Drug intelligence / Profile preview

E-4010

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

E-4010 is a newly synthesized, potent, and selective orally active phosphodiesterase 5 (PDE5) inhibitor. It has demonstrated efficacy in attenuating hypoxic pulmonary hypertension in rats by causing a long-lasting reduction in mean pulmonary arterial pressure without significant effects on systemic arterial pressure, cardiac output, or heart rate. Long-term treatment with E-4010 also reduced right ventricular hypertrophy and pulmonary arterial remodeling, likely by increasing cGMP levels in the pulmonary vascular smooth muscle.

Targets

PDE5 (Phosphodiesterase 5A)

Beyond the preview

Go deeper on E-4010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E-4010.

Explore the full profile